NTCOC
GEVA

Northern Trust Company of Connecticut’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Northern Trust Company of Connecticut’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$78K Hold
1,200
– – ﹤0.01% 1902
2013
Q3 		$76K Sell
1,200
-14,070
-92% -$693K ﹤0.01% 1879
2013
Q2 		$641K Buy
+15,270
New +$696K ﹤0.01% 1419

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Company of Connecticut's GEVA Position: Q4 2013 in Review

Northern Trust Company of Connecticut held its SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) position steady in Q4 2013 at 1,200 shares worth $78K. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Northern Trust Company of Connecticut first reported a position in GEVA in Q2 2013 and has held it in 3 quarters since. The position peaked at $641K in Q2 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • Northern Trust Company of Connecticut held 1,200 shares of SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $78K as of Q4 2013.
  • Northern Trust Company of Connecticut left its SYNAGEVA BIOPHARMA CORP COM STK (DE) share count unchanged in Q4 2013.
  • SYNAGEVA BIOPHARMA CORP COM STK (DE) made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1902 holding.
  • Northern Trust Company of Connecticut first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and has held it in 3 quarters since.
  • Northern Trust Company of Connecticut's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $641K in Q2 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.